

Supplementary Material




Figure S1. Effects of the combination therapy with an AKT inhibitor (AZD5363) and mTOR inhibitors (AZD2014 and BEZ235) on PI3KCA-mutated and mTOR wild-type bladder cancer cells. The effects of the combination of AZD5363 and mTOR inhibitors on bladder cancer cell lines were determined using CellTiter Glo. 253J-BV cells were treated with AZD5363 (3 μ M), mTOR inhibitors (1 μ M AZD2014 and 0.5 μ M BEZ235) or the combination of both for 5 days. The results are presented as the mean \pm SD for triplicate wells and are representative of three independent experiments.




Figure S2. Dose-response matrix for a two-drug combination. Matrix block experiment to determine viability, as estimated with the CellTiter Glo assay.